Roche Upbeat On Ocrevus Despite Consensus Miss
COVID-19 And Competition Slows Growth
Fewer patients with multiple sclerosis are switching treatment during the pandemic but despite that, and the arrival of competition from Novartis's Kesimpta, Roche insists Ocrevus growth remains strong.
